Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Jeff Dykan is Director at Regentis Biomaterials. OQRO lists 2 transactions filed with the SEC under this name, the latest on Jul 13, 2026, each linked to the official Form 4.
Director
Disclosures on record
2
Companies involved
1
Regentis BiomaterialsRGNT
2 disclosures · Jul 2026
Jul 9, 202613Kdisclosed Jul 13
DetailsOfficial recordJul 9, 202625Kdisclosed Jul 13
DetailsOfficial recordJeff Dykan bought shares on the open market in 2022 and 2023, and has not bought since 2023. Sales in 3 of the 11 years since 2016.
Jeff Dykan reported 4 open-market purchases and 20 sales since 2016; purchases in 2 different years, most recently 2023.
| Year | Bought | Sold |
|---|---|---|
| 2023 | $15K2×2 trades | — |
| 2022 | $25K2×2 trades | — |
| 2021 | — | $6.3K1×1 trade |
| 2017 | — | $265K2×2 trades |
| 2016 | — | $1.87M17×17 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Jeff Dykan bought shares on the open market in 2022 and 2023, and has not bought since 2023. Sales in 3 of the 11 years since 2016.
In SEC filings since 2016: the latest open-market purchase is from 2023; the latest open-market sale is from 2021.
Lifeward (LFWD), from 2016 to 2023: 4 purchases and 20 sales.
Jeff Dykan reported 4 open-market purchases and 20 sales here, 2016 to 2023.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
